Assessment of a Stool Symptom Screener and Understanding the Opioid-Induced Constipation Symptom Experience

Patient

Volumn 8, Issue 4, 2015, Pages 317-327

  Coyne, Karin S ^a   Currie, Brooke M ^a   Holmes, William C ^b   Crawley, Joseph A ^b  

^a EVIDERA   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISACODYL; DOCUSATE SODIUM; FLEET ENEMA; ISPAGULA; LUBIPROSTONE; MACROGOL 3350; METHYLCELLULOSE; MORPHINE; OXYCODONE; PARACETAMOL; SENOKOT; LAXATIVE; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; BLOATING; CLINICAL ASSESSMENT TOOL; COMPREHENSION; CONSTIPATION; DISABILITY; DRUG INDUCED DISEASE; FEMALE; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; NECK PAIN; OPIOID INDUCED CONSTIPATION; ORANGE JUICE; PERSONAL EXPERIENCE; PRIORITY JOURNAL; SEMI STRUCTURED INTERVIEW; STOOL SYMPTOM SCREENER; SYMPTOM; UNEMPLOYMENT; UNITED STATES; CHEMICALLY INDUCED; CHRONIC DISEASE; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; SOCIOECONOMICS; STANDARDS;

ANALGESICS, OPIOID; CHRONIC DISEASE; CONSTIPATION; FEMALE; HUMANS; LAXATIVES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; SURVEYS AND QUESTIONNAIRES;

EID: 84938823340     PISSN: 11781653     EISSN: 11781661     Source Type: Journal    
DOI: 10.1007/s40271-014-0087-7     Document Type: Article

References (11)

1. Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag. 2009;5(3):137–44.
2. Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ. 2001;322(7295):1154–8.
3. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61(7):1181–7.
4. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74(8):1347–54.
5. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A Suppl):11S–8S.
6. Überall MA, Müller-Schwefe GHH. Obstiless reports impact of opioid-induced side effects. Section in “International Perspectives on Pain and Palliative Care” by Elon Eisenberg. Pain Palliat Care. 2009;23(1):79–81.
7. Frank L, Kleinman L, Farup C, Taylor L, Miner P Jr. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol. 1999;34(9):870–7.
8. Slappendel R, Simpson K, Dubois D, Keininger DL. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain. 2006;10(3):209–17.
9. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10(1):35–42.
10. Cook S, Bell T, Sweeney C, Fehnel S, Hollis K. Impact on quality of life of constipation-associated GI symptoms related to opioid treatment in chronic pain patients: PAC-QOL results from the opioid survey. J Pain. 2007;9:S71 (Abstract 883).
11. Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol. 2005;40(5):540–51.